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Abstract—The Asia Renal Denervation Consortium consensus conference of Asian physicians actively performing renal 
denervation (RDN) was recently convened to share up-to-date information and regional perspectives, with the goal 
of consensus on RDN in Asia. First- and second-generation trials of RDN have demonstrated the efficacy and safety 
of this treatment modality for lowering blood pressure in patients with resistant hypertension. Considering the ethnic 
differences of the hypertension profile and demographics of cardiovascular disease demonstrated in the SYMPLICITY 
HTN (Renal Denervation in Patients With Uncontrolled Hypertension)-Japan study and Global SYMPLICITY registry 
data from Korea and Taiwan, RDN might be an effective hypertension management strategy in Asia. Patient preference 
for device-based therapy should be considered as part of a shared patient-physician decision process. A practical 
population for RDN treatment could consist of Asian patients with uncontrolled essential hypertension, including 
resistant hypertension. Opportunities to refine the procedure, expand the therapy to other sympathetically mediated 
diseases, and explore the specific effects on nocturnal and morning hypertension offer a promising future for RDN. 
Based on available evidence, RDN should not be considered a therapy of last resort but as an initial therapy option that 
may be applied alone or as a complementary therapy to antihypertensive medication.
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Recent multicenter international sham-controlled clinical trials have demonstrated statistically and clinically sig-
nificant reductions in blood pressure (BP) after renal dener-
vation (RDN) in patients with uncontrolled hypertension1–3 
and have added important scientific perspective to the neu-
tral results of the earlier SYMPLICITY HTN-3 trial.4 The 
clinical positioning of this innovative treatment should now 
be considered within the overall clinical hypertension man-
agement strategy.5
Hypertension profiles and the demographics of hyper-
tension-related cardiovascular disease (CVD) vary with eth-
nicity. In Asia, the impact of hypertension on CVD is greater, 
and the rate of uncontrolled hypertension is higher than in 
Western countries.5,6 The goal of hypertension manage-
ment strategies should be towards perfect 24-hour BP con-
trol, thus reducing the rate of CVD events in Asia towards 
zero.7 However, to date, there has been no discussion or 
consensus on the positioning of RDN for Asian hypertension 
management.
The Asia Renal Denervation Consortium (ARDeC) con-
sensus conference was recently convened to share up-to-date 
information and regional perspectives on the scientific ev-
idence for renal denervation. The consortium consisted of 
Asian physicians who actively perform RDN in a variety 
of regions, including Hong Kong, Japan, Korea, Malaysia, 
Singapore, Taiwan, Thailand, and Vietnam, and was convened 
independent of any clinical or healthcare organization. The 
goal of the consortium was to achieve consensus recommen-
dations on RDN that might help inform healthcare profession-
als in Asia. Individual members reported on various aspects 
of RDN for hypertension focusing on four major questions as 
detailed below, followed by group discussion of the data and 
consensus recommendations. Here, we report the consensus 
from the first ARDeC conference, held in 2019.
Review
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Current Evidence
First-Generation Clinical Trials
The early proof-of-concept SYMPLICITY HTN-1 and the ran-
domized controlled SYMPLICITY HTN-2 trials reported dra-
matic BP reductions following RDN.8,9 Initial enthusiasm stalled 
after the release of results of the SYMPLICITY HTN-3 study.4 
SYMPLICITY HTN-3 was a blinded, randomized controlled 
trial in which 535 subjects with uncontrolled treatment-resistant 
hypertension were randomized to RDN or a sham procedure. No 
statistically significant differences between the 2 groups were 
observed at the 6-month follow-up, although office and 24-hour 
BP had decreased significantly in both groups. Post hoc analysis 
of SYMPLICITY HTN-3 identified several confounding factors 
that could help to explain the unexpected neutral results, espe-
cially the significant decrease in BP seen in the sham-control 
group.10 First, the use of medications to treat hypertension and 
the possibility of patient noncompliance with treatment were not 
adequately addressed in the study protocol. Second, the study 
population was predominantly North American with a signifi-
cant proportion of Afro-Americans. Third, substantial procedural 
variability may have occurred due to inexperience among study 
investigators. Considering all these limitations, the SPYRAL 
HTN clinical trial (Global Clinical Study of Renal Denervation 
With the Simplicity Spyral Multi-Electrode Renal Denervation 
System in Patients With Uncontrolled Hypertension) program 
was initiated to reliably determine the efficacy of RDN for the 
treatment of hypertension.
The efficacy of RDN was further supported by the results 
of the multicenter, open-label, randomized controlled French 
DENERHTN study (Renal Denervation for Hypertension), 
comparing RDN with stepped-care standardized antihyper-
tensive treatment in 121 patients with resistant hyperten-
sion.11 At the 6-month follow-up, there were significantly 
greater reductions in daytime ambulatory BP in the RDN 
group versus control.11
In addition to randomized trials, the Global SYMPLICITY 
Registry (GSR) has enrolled over 2700 real-world patients 
and >2300 have now been followed for 3 years.12 The GSR 
data showed that, when used in routine clinical practice out-
side a clinical trial setting, the BP response to RDN was con-
sistent with the results obtained in randomized trials. The 
safety record within GSR has been very good, and the registry 
has recorded significant office and 24-hour BP reductions out 
to 3 years in multiple high-risk subpopulations including the 
elderly, and patients with diabetes mellitus, chronic kidney di-
sease, isolated systolic hypertension, and arrhythmias.13,14
Second-Generation Trials
After carefully considering the shortcomings of the 
SYMPLICITY HTN-3 trial, newer second-generation RDN 
devices were evaluated in randomized trials. The SPYRAL HTN-
OFF MED trial was a multicenter, international, single-blind, 
randomized, sham-controlled trial using the second-generation 
multielectrode Symplicity Spyral catheter system and including 
80 patients with mild to moderate hypertension not currently 
prescribed antihypertensive medication (either drug naïve or dis-
continued medication).3 Three-month changes in office and am-
bulatory systolic BP (SBP) and diastolic BP from baseline were 
statistically significant in the RDN group (Figure 1), and there 
were no significant changes in BP from baseline in the sham-
control group (P<0.05 for between-group comparison).
SPYRAL HTN–ON-MED was also a multicenter, inter-
national, single-blind, randomized, sham-controlled trial, con-
ducted at the same enrolling centers as SPYRAL HTN-OFF 
MED.2 Patients with mild to moderate hypertension who had 
been prescribed 1–3 standard antihypertensive drugs were 
enrolled. Treatment with RDN was associated with statisti-
cally significant changes in BP from baseline to 6 months with 
no significant change in the sham-control group (Figure 1). 
No major procedural or clinical safety events were observed 
in either the OFF-MED or ON-MED trials.2,3 Both trials have 
been extended to collect additional safety and effectiveness 
data (SPYRAL Pivotal trial and ON-MED IDE trial).
The RADIANCE-HTN SOLO trial was a multicenter, in-
ternational, single-blind, randomized, sham-controlled study of 
the ultrasound catheter-based Paradise renal denervation system 
in patients with moderate uncontrolled hypertension.1 A signif-
icant reduction in daytime and 24-hour ambulatory BP was 
observed in the RDN versus sham (Figure 1), with no major 
procedural or clinical safety events observed in either group.1
The single-blind, single-center, 3-arm randomized 
RADIOSOUND-HTN (Randomized Comparison of Ultrasound 
Versus Radiofrequency Denervation in Patients With Therapy 
Resistant Hypertension) study compared 3 different RDN tech-
niques, including radiofrequency ablation of the main renal ar-
tery (RFM-RDN), radiofrequency ablation of the main renal 
artery, branches, and accessories (RFB-RDN), and ultrasound-
based ablation of the main renal artery (USM-RDN), in patients 
with resistant hypertension.16 Reductions in daytime SBP were 
greater with USM-RDN versus RFM-RDN, and there was no 
significant difference between USM-RDN and RFB-RDN. The 
proportion of patients with a ≥5 mm Hg reduction in BP was not 
significantly different between the 3 groups.16
Several additional RDN catheter systems have been devel-
oped and are currently in the early stages of clinical testing. 
The Peregrine catheter ablation system (Ablative Solutions, 
MI) includes a 3-needle delivery system to perform chemical 
RDN via microdoses of dehydrated alcohol.17 In the first-in-
man trial, mean office SBP decreased from 175 to 151 mm Hg 
(−24 mm Hg). The IberisBloom radiofrequency energy-based 
RDN catheter system (Terumo, Tokyo, Japan) incorporates a 
4-electrode catheter design, similar to the SYMPLICITY de-
vice. A single-arm registry is currently ongoing, and a ran-
domized trial is planned. Golden Leaf (Shanghai Golden 
Leaf Med-Tec Co, Shanghai, China) has also developed a 
6-electrode basket design radiofrequency energy-based RDN 
catheter.18 One study showed that office and ambulatory SBP 
significantly decreased by 11.5 and 7.5 mm Hg, respectively, 
at 3 months. A sham-controlled randomized trial is planned.
Notably, a recent meta-analysis based exclusively on 
sham-controlled trials showed a significantly greater reduc-
tion in daytime ambulatory SBP in second-generation RDN 
trials compared with first-generation RDN trials (mean dif-
ference in 24-hour SBP: −4.9 mm Hg [95% CI, −7.1 to −2.6 
mm Hg]).19 Another meta-analysis also indicated significant 
office and ambulatory BP-lowering effects of RDN in ran-
domized trials after removing the confounder of unplanned 
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medication changes (mean difference in 24-hour SBP: −6.1 
mm Hg [95% CI, −8.7 to −3.5 mm Hg]).20
There are currently few data on the effects of RDN on hard 
clinical outcomes, although early reports of surgical splanchni-
cectomy showed improved mortality compared with a matched 
control group, independent of BP reduction.21 Nevertheless, the 
relationship between decreased BP and reductions in cardiovas-
cular risk is well-established, and relatively modest reductions 
in office SBP are strongly associated with cardiovascular risk 
reduction.22 Data from a systematic review ad meta-analysis 
calculated that a 10 mm Hg reduction in SBP was associated 
with a 13% reduction in all-cause mortality, a 27% reduction in 
the rate of stroke events, and 28% reduction in the risk of devel-
oping heart failure (all independent of baseline BP).22 Thus, al-
though prospective outcome trials of RDN are highly desirable, 
these may be challenging to practically design and execute, 
and use of surrogate end points may provide a more feasible 
approach to determining the clinical value of RDN.
Summary: First and Second Generation RDN Trials
• Early clinical trials of RDN have repeatedly demonstrat-
ed the efficacy and safety of this treatment modality for 
lowering BP in patients with resistant hypertension.
• All second-generation RDN trials showed that RDN 
significantly reduced BP without any major safety 
concerns.
• Recent meta-analyses showed a significantly greater re-
duction in daytime ambulatory SBP in second- versus 
first-generation RDN trials.
• Several ongoing pivotal trials will further evaluate the 
safety and efficacy of RDN in large populations of pa-
tients with hypertension.
What Is the Asian Perspective for RDN?
The characteristics of hypertension and hypertension-related 
CVD show key racial differences in Asian populations.6 First, 
stroke occurs more frequently than myocardial infarction in 
Asian (particularly East Asian) countries,23 whereas myocar-
dial infarction is more common than stroke in the rest of the 
world.24 Second, although East Asian populations are gener-
ally slimmer than whites, the prevalence of hypertension in 
Asia is similar to global rates.25 Cutoff values for both body 
mass index and waist circumference and the presence of hy-
pertension and other metabolic syndrome features were low-
est in East Asian populations and highest in South Asian 
populations.26 This suggests that Asian populations, partic-
ularly East Asians, are prone to developing obesity-related 
metabolic derangements, including hypertension. Third, 
masked hypertension, which includes morning hypertension 
and nocturnal hypertension, is more prevalent in Asians than 
in Westerners,27,28 and masked hypertension is associated with 
increased CVD risk.29–31 Comparing the baseline 24-hour BP 
profiles of resistant hypertension between Japanese patients 
enrolled in SYMPLICITY HTN-J and white and black 
patients enrolled in the SYMPLICITY HTN-3 with iden-
tical enrollment criteria, Japanese patients had significantly 
higher morning BP and more pronounced morning BP surge, 
despite similar inclusion criteria and office BP across the 3 
ethnic groups.15 Masked hypertension is a hallmark of obe-
sity-related hypertension,32 which causes increased circulating 
blood volume (and therefore nocturnal hypertension) due to 
decreased sodium excretion and decreased baroreceptor sensi-
tivity (and therefore morning BP surge) due to increased sym-
pathetic activity.33,34 In addition, the nondipper/riser pattern of 
nocturnal BP is more common in Asians than in Westerners.35 
Finally, East Asian populations have at least a 2-fold higher 
sensitivity to the β-blocking effects of propranolol than white 
populations.36 Overall, these observations suggest that Asian 
populations might be more sensitive to sympathetic modula-
tion, thereby making RDN an attractive BP-lowering strategy.
SYMPLICITY HTN-J was the first prospective random-
ized study to focus specifically on the uncontrolled Asian hy-
pertensive population.37,38 Differences in SBP reductions after 
RDN of only the main renal artery using the first-generation 
RF catheter were not significantly different from those seen in 
the control group (receiving standard pharmacotherapy), po-
tentially due to a lack of statistical power due to early discon-
tinuation of the trial. However, the magnitude of reductions 
in 24-hour SBP after RDN were similar to those achieved in 
the subsequent sham-controlled SPYRAL HTN–OFF-MED, 
–ON-MED, and RADIANCE-HTN SOLO trials using next-
generation technology (Figure 1).37–40 Although Japanese 
patients were included in both SPYRAL HTN trials,2,3 the 
numbers enrolled were too small to detect any ethnic differ-
ences in the BP-lowering effect. Recently, the effectiveness 
of ablation of both the main renal artery and its branches has 
been shown to be superior to that of main renal artery ablation 
only for reducing norepinephrine content in the kidney in pre-
clinical studies, and for BP reduction in clinical studies.16,41 
Figure 1. Comparison of 24-h systolic 
blood pressure (SBP) changes from baseline 
to follow-up in recent randomized renal 
denervation trials. SBP reductions in the 
SYMPLICITY HTN-Japan study (the only 
randomized trial of renal denervation [RDN] 
in a predominantly Asian population) were 
similar to those in the global trials despite use 
of first-generation single electrode RF catheter 
technology.1–3,15
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These data suggest that RDN might be as effective, or perhaps 
even more effective, in Asians than in Westerners.
Time-trend analysis of SYMPLICITY HTN-J showed 
that reductions in ambulatory BP after RDN occurred consist-
ently over the 24-hour period, including nighttime and in the 
morning (Figure 2). Given that nighttime and early morning 
hypertension are associated with higher CVD risk independ-
ently of office BP in Asian patients with hypertension,42–46 the 
clinical implications of RDN therapy could be greater in Asian 
countries. Notably, the recent long-term follow-up results of 
SYMPLICITY HTN-J showed significant and marked reduc-
tions in office BP with RDN, without significant procedural 
complications in Japanese patients (Figure 3).
The first reported comparison outcomes of RDN in an 
Asian population were from the Korean Registry,47 a sub-
analysis of the GSR.12 Following RDN of both renal arteries, 
overall registry data showed that office SBP was significantly 
reduced at 6 months (168.3±13.9 at baseline to 148.8±18.4 
mm Hg at 6 months; P<0.001) and 12 months (141.0±17.2 
mm Hg; P<0.001 versus baseline). Changes in SBP at 6 and 
12 months were −19.4±17.2 and −27.2±18.1 mm Hg, respec-
tively (both P<0.001 versus baseline).47 Comparing BP reduc-
tions between patients from GSR Korea and a matched subset 
of white GSR patients (n=169), changes in SBP at 6 months 
were similar in the 2 groups (−19.4±17.2 versus −20.9±21.4 
mm Hg, respectively; P=0.547 [unadjusted] and P=0.998 
[adjusted for baseline BP]), but at 12 months SBP reductions 
were greater in Koreans versus whites (−27.2±18.1 versus 
−20.1±23.9 mm Hg, respectively; P=0.004 [unadjusted] and 
P=0.002 [adjusted]). No procedure- or device-related adverse 
events were reported in the Korean subgroup.47 Multivariate 
analysis adjusting for all baseline characteristics and base-
line medication classes identified a significant association 
between higher baseline office BP and a greater reduction in 
SBP at both 6 and 12 months.47 Importantly, Korean patients 
were more likely than white patients to have a greater reduc-
tion in 12-month SBP,47 suggesting a potential role for racial 
differences in the effects of RDN. Long-term follow-up of 
GSR Korea also showed that long-term SBP reductions were 
greater in Korean than in white patients.48
Recently, another analysis of the GSR was reported for the 
Taiwan subgroup (GSR-Taiwan).49 Of the 26 patients enrolled 
(mean age 59.1±13.8 years), 8 were treated with the Symplicity 
Flex catheter and 18 were treated with the Symplicity Spyral 
catheter. Baseline office SBP was 168.2±19.8 mm Hg and di-
astolic BP was 89.0±14.3 mm Hg. Office BP reductions after 
Figure 2. Ambulatory systolic blood pressure (SBP)-lowering effect of renal denervation (RDN) based on 24-h diurnal variation in different clinical trials. Blood 
pressure reductions showed similar 24-h patterns between the SPYRAL HTN-OFF MED (A,B) SPYRAL HTN-ON MED (C,D) and SYMPLICITY HTN-Japan 
(E,F) trials. 1,2,37
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RDN were sustained for up to 3 years in the Symplicity Flex 
group and up to 2 years in the Symplicity Spyral group. In 
the Symplicity Flex group, office SBP reductions at 3 months 
and 3 years were 14.9±14.7 and 29.7±25.9 mm Hg, respec-
tively (both P<0.05 versus baseline). In the Symplicity Spyral 
group, reductions in office SBP at 3 months and 2 years 
were 21.2±28.7 and 42.4±10.7 mm Hg, respectively (both 
P<0.05 versus baseline). Collectively, these analyses indicate 
that RDN should be a promising hypertension management 
strategy option in Asia.
Summary
• Long-term follow-up in the SYMPLICITY HTN-J study 
showed that significant reductions in BP were sustained 
for at least 3 years after RDN without any significant 
intervention-related adverse effects.
• Subanalyses from the Global SYMPLICITY Registry 
showed significant and sustained BP reductions after 
RDN in the Korean and Taiwanese subpopulations.
• The proportion of Korean GSR patients with a substan-
tial reduction in 12-month SBP was greater than that for 
white patients.
Which Patients Are Most Likely to  
Benefit From RDN?
The promising results of RDN in Asian populations may 
partly be due to higher salt sensitivity and higher salt intake 
in Asians than in Westerners. Dietary modifications are im-
portant and may be effective to reduce salt intake, but mean-
ingful and persistent dietary changes often fail. Meanwhile, 
the risk of end-organ damage due to uncontrolled hyperten-
sion remains high. Reduced baroreflex sensitivity increases 
BP variability that may be further exacerbated by higher salt 
intake.38 Chronic baroreflex failure may further lead to an ad-
verse pressure-natriuresis response.38 Likewise, age-related 
baroreflex failure leads to extended increases in BP levels and 
BP variability in Asians with higher salt sensitivity and higher 
salt intake. In addition, nondipper and riser pattern of noc-
turnal BP partly depend on the increased circulating volume 
which is associated with higher salt sensitivity and salt intake.
Available data from Asian populations also suggest that 
RDN is a feasible BP-lowering strategy for uncontrolled 
hypertension across multiple clinical scenarios including 
antihypertensive-naïve patients, those on treatment and 
patients in whom treatment has been discontinued. In the 
Asian prospective J-HOP (Japan Morning Surge - Home 
Blood Pressure) study, morning and nocturnal uncontrolled 
hypertension were associated with increased risk of CVD, 
especially stroke, regardless of office BP control status.45 
Because of the fact that the BP-lowering effects of antihy-
pertensive drug therapy generally decrease overnight before 
typical morning dosing, nighttime and morning BP control 
may represent a relative blind spot for current antihyperten-
sive medication regimens.15 Thus, RDN could be applied as 
both adjunctive and alternative complementary therapy for the 
management of hypertension.
RDN affects both sympathetic efferent and afferent sen-
sory nerve pathways to reduce BP (Figure 4).5,50 Sympathetic 
efferent nerve ablation inhibits the renin-angiotensin-aldoste-
rone system resulting in increased renal blood flow, reduced 
salt sensitivity, and decreased urinary excretion of sodium. 
Especially at nighttime, the circulating volume decreases to 
lower BP because the nondipping pattern of nocturnal BP is a 
compensation mechanism designed to excrete excess sodium 
for patients with increased circulating volume.33,34 Thus, RDN 
should be effective in Asians with higher salt intake and higher 
salt sensitivity, but prospective studies are needed to clearly 
define the direct effects of sodium and volume status on the 
response to RDN in Asian populations. Furthermore, afferent 
nerve ablation suppresses the central sympathetic outflow to 
increase baroreceptor sensitivity. As a result, exaggerated BP 
variability, such as morning BP surge and sleep-triggered BP 
surge, are decreased.
Combined Hypertension Versus Isolated Systolic 
Hypertension
Previous studies have shown that baseline BP, diastolic BP 
variability,51 combined systolic-diastolic hypertension,52 
24-hour ambulatory heart rate,53 renal artery vasodilatation,54 
aortic pulse wave velocity,55 and central pulse pressure56 were 
potential predictors of response to RDN. Although none of 
these are direct measures of sympathetic activity, the obser-
vation that patients with combined systolic-diastolic hyper-
tension were more responsive to RDN was considered in the 
design of 3 RDN 2.0 trials. Evidence that isolated systolic 
hypertension patients may respond less well to RDN mainly 
Figure 3. Change in office blood pressure (BP) 
after renal denervation (RDN): 3-y follow-up of 
SYMPLICITY HTN-J.37
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comes from pooled data from SYMPLICITY HTN-3 and 
GSR, and other studies.52 However, these data have a number 
of limitations, including the retrospective nature of the analy-
ses. Furthermore, significant differences in baseline BP, heart 
rate, and demographic variables including age and comorbidi-
ties make meaningful statistical comparisons between patient 
groups challenging, despite multivariate adjustments. Indeed, 
a recent subanalysis of a prospective, randomized trial of 
RDN using both RF and ultrasound techniques found no dif-
ference in ambulatory BP reductions between patients with 
isolated systolic hypertension and those with combined hyper-
tension after appropriate adjustment for baseline BP, which is 
typically higher in the combined hypertension cohort.55 Thus, 
the hypothesis that RDN is less effective in isolated systolic 
hypertension remains unproven and warrants further investi-
gation. Interestingly, baseline heart rate may also be a useful 
identifier of neurogenic hypertension because a recent post 
hoc analysis of the SPYRAL HTN-OFF MED study showed 
that higher baseline 24-hour ambulatory heart rate (>74 beats/
min) predicted greater BP reductions after RDN.53
In summary, the search for reliable predictors to identify 
responders to RDN is important. However, current predictors 
of a more pronounced BP response to RDN, including base-
line BP, combined uncontrolled hypertension, lower pulse 
pressure (<100 mm Hg),55 and higher 24-hour ambulatory 
heart rate, are based only on evidence from retrospective post 
hoc analyses. Whether these findings can be replicated in pro-
spective studies awaits verification.
Uncontrolled Versus Treatment-Resistant 
Hypertension, Versus Patient Preference
Evidence from randomized controlled trials and meta-anal-
yses of RDN, which have included a substantial number of 
patients from Asia, clearly showed that the BP-lowering ef-
ficacy of RDN was related to baseline BP and independent 
of the number of prescribed antihypertensive medications. 
Therefore, RDN should not be reserved only for patients with 
resistant hypertension. RDN could serve as a complemen-
tary BP-lowering strategy in situations where BP targets are 
clearly difficult to achieve and maintain.
Masked uncontrolled hypertension, defined as controlled 
office BP but uncontrolled home or ambulatory BP, occurs in 
≈30% of treated hypertensive patients.57 Masked uncontrolled 
hypertension includes morning and nocturnal uncontrolled 
hypertension and is more frequent (≈50%) in Asian popula-
tions,28 potentially due, in part, to higher salt intake and higher 
salt sensitivity.6,33,58 Home and ambulatory BP measurements 
should be routinely required, particularly for Asian patients 
with hypertension. Given the 24-hour sustained BP reduc-
tions including nighttime and morning BPs achieved in the 
SYMPLICITY HTN-J, SYMPLICITY HTN-3, and 3 RDN 
2.0 trials,37,38 it would seem reasonable to recommend RDN, 
in addition to antihypertensive dosage adjustment.59
Although clinically meaningful BP reductions can be 
achieved by various lifestyle interventions and antihyperten-
sive agents, nationwide BP control rates remain poor world-
wide and are <50% in many Asian countries.60–62 Similar to 
other chronic diseases, one essential reason for the unsatisfac-
tory control rates of hypertension is poor lifestyle/medication 
adherence, either by intention (patient preference), forgetful-
ness or other educational, psychological or socioeconomic 
factors.63 The impact of nonadherence on long-term hyper-
tension control is tremendous and often underestimated,63,64 
as reflected by the marked difference in hypertension control 
rates between hospitalized patients compared with general 
populations. To reduce this gap, patient preference regarding 
long-term medication therapy should be carefully explored 
and considered in determining the most appropriate antihyper-
tensive strategies for an individual patient as part of a shared 
decision-making process.65 Those who are intolerant of or 
nonadherent to antihypertensive agents for any reason could 
be managed using RDN given its excellent safety profile and 
sustained BP-lowering efficacy.
Ethnicity
Significant ethnic differences in various aspects of hyperten-
sion could impact the responsiveness to RDN.66 Asia-specific 
features of hypertension and the response to RDN have been 
summarized above. Given the susceptibility of Asian popu-
lations to hypertension and the fact that responses to RDN 
Figure 4. Potential mechanisms for the 
effects of renal denervation (RDN) on 24-h 
diurnal blood pressure variation.50 RDN may 
contribute to the achievement of perfect blood 
24-h pressure control via distinct efferent and 
afferent mechanisms that might differentially 
effect daytime, nighttime, and morning blood 
pressure control.
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appear to be at least equivalent, if not greater over the longer-
term, to those in whites, RDN might be particularly beneficial 
in Asian populations.
Summary: Practical Population for Treatment 
With RDN
• Asian patients with hypertension, including those with 
resistant hypertension
• Patients with masked uncontrolled hypertension
• Patients with uncontrolled hypertension and established 
atherosclerotic cardiovascular disease (stroke, coronary 
artery disease, aortic dissection, etc) and heart failure
• Patients intolerant of, or nonadherent to, antihyperten-
sive drug therapy
• Patients with combined uncontrolled hypertension, 
lower pulse pressure (<100 mm Hg), or increased 24-
hour ambulatory heart rate (>74 beats/min)
How Can the RDN Procedure be  
Optimized Further?
Anatomic studies in animals showed that complete 4-quadrant 
ablation was correlated with circumferential destruction of 
nerves along renal arteries, translating to reduced renal tissue 
norepinephrine levels.67 In addition, human autopsy studies 
demonstrated that the periarterial sympathetic nerves converge 
from proximal to distal along the renal arteries.68 The afferent 
sympathetic fibers are mainly located at the proximal segment 
with decreasing ratio of prevalence of afferent/efferent fibers 
in the direction from proximal to distal. Furthermore, periar-
terial sympathetic nerve fibers are closer to the arterial lumen 
at the distal segment. At distal regions, ≈75% of nerves are 
within 3 mm of the lumen, which is well within the range of 
damage for radiofrequency ablation. Animal studies show that 
combined main artery plus side branches ablation produced 
the greatest drop in renal norepinephrine.41 Similar findings 
have been reported in human clinical studies.69 The presence 
of accessory branches also affects the completeness of abla-
tion.70 The total number of lesions delivered is also crucial 
because it was recently shown that increased number of abla-
tions was a predictor of office SBP reduction at 6 months in 
SYMPLICITY HTN-3.10 These observations suggest that both 
main artery and distal branch ablations are important for com-
plete nerve destruction.
Identification of Nerve Destruction
A safe, accurate, and clinically practical method to identify 
complete nerve destruction after a renal denervation proce-
dure remains an unmet need. Accurate measurement of sym-
pathetic activity may provide an alternative study end point or, 
more importantly, immediate feedback on procedural success 
by estimating the completeness of nerve destruction. The rate 
of norepinephrine spillover, as determined by radiotracer dilu-
tion, is a well-established physiological method for measuring 
sympathetic activity in vivo.71 RDN reduced renal norepi-
nephrine spillover by 47% and total body norepinephrine 
spillover by 28% at 15 to 30 days after the procedure. In the 
SYMPLICITY HTN-1 trial, therefore confirming its effect on 
efferent renal nerves.9 However, such testing is not commonly 
available in hospital laboratories. Measurement of muscle 
sympathetic nerve activity (MSNA) is another marker of cen-
tral sympathetic activity measured by microneurography of 
postganglionic sympathetic nerves. Hering et al72 showed the 
reduction of MSNA at 3 months after RDN in a small number 
of patients, thereby documenting an effect on afferent renal 
nerves.73 However, these findings were not reproduced in sub-
sequent studies.74,75 Also, reductions in MSNA were not corre-
lated with reductions in BP after RDN.72 Therefore, conclusive 
evidence is still required to show whether the measurement of 
MSNA is clinically useful in guiding the RDN procedure.
Direct assessment of sympathetic activity either by nor-
epinephrine spillover or MSNA seems impractical in daily 
practice. Noninvasive measurement of autonomic activity 
via cardiac baroreflex sensitivity assessed from R-R interval 
analysis or from SBP values by phase rectified signal aver-
aging indicated that impaired cardiac baroreflex sensitivity 
predicted response to RDN.76 However, assessment of cardiac 
baroreflex is limited to patients who are in sinus rhythm and 
also requires noninvasive equipment that can continuously 
monitor arterial pressure.
Renal nerve stimulation (RNS) or mapping is a promising 
method to demonstrate interaction with the renal sympathetic 
nervous system in vivo. Initial animal study data first reported 
that rapid electrical stimulation of renal arterial nerves was 
associated with a transient rise in BP.77 A recent experimental 
study demonstrated that transvascular pacing of aorticorenal 
ganglia might be useful as a procedural end point.78 Subsequent 
studies also reported similar findings in humans.79,80 In one 
small study, de Jong et al81 demonstrated that completeness 
of RDN might be assessed by RNS, which in turn might pre-
dict the BP response to RDN. After RDN, a more blunted BP 
rise response with RNS was associated with greater reduction 
of ambulatory BP from 3 to 6 months.81 Interestingly, stud-
ies using RNS to predict response to RDN in treatment of 
atrial fibrillation82 and ventricular tachycardia83 showed sim-
ilar findings. These proof-of-concept studies involving RNS 
were often conducted with the use of conventional catheters 
designed for electrophysiology studies, followed by RDN 
using currently available RDN catheters. To facilitate the 
process of RNS, a dedicated device, the ConfidenHT system 
(Pythagoras Medical Ltd, Herzliya, Israel) has recently be-
come available.84 The SyMAP CATH ITM (SyMap Medical 
[Suzhou], Ltd, China) is another potential RNS, mapping and 
denervation device. The current SMART OFF-MED random-
ized controlled trial is enrolling hypertensive patients in the ab-
sence of antihypertensive medications, using SyMAP CATH 
ITM catheter and SYMPIONEER Stimulator/Generator for 
combined stimulation, mapping and denervation using one 
single device (URL: http://www.clinicaltrials.gov. Unique 
identifier: NCT02761811).
Procedural Efficiency
Preprocedural planning using magnetic resonance angiog-
raphy or computed tomography angiography to identify any 
renal stenosis, location of renal artery ostia and presence of 
any accessory branches might be able to reduce procedural 
time. The RDN procedure is typically performed under local 
anesthesia and conscious sedation. Guiding catheters with ap-
propriate configuration engaging the renal artery ostia should 
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be chosen after a nonselective aortogram. The use of sec-
ond-generation multielectrode ablation catheters also helps to 
shorten the procedure time. If femoral access is chosen, the 
use of a vascular closure device should be considered to facil-
itate early mobilization and discharge from hospital. For the 
same purpose, the radial approach could also be considered if 
the selected device is radial approach compatible.
Summary
• Completeness of the RDN procedure should be ensured 
by increasing the number of ablations, ensuring circum-
ferential lesion distribution, treating the main artery 
plus side branches, and even accessory branches when 
possible.
• Incorporating preprocedural imaging, electro-anatomic 
mapping, and using a radial access approach may reduce 
time and contrast use during the RDN procedure.
• Further research on RNS may help guide RDN proce-
dure intraoperatively.
What Hypotheses Need to be Tested in New 
Clinical Trials?
Expanding Existing Indications and Usage
Reductions in BP after RDN can vary between patients, and 
there remains an unmet clinical need for ways to identify 
those who will have the best response. Some possible candi-
date conditions associated with sympathetic hyperactivity are 
shown in Figure 5.85
Considering the unique characteristics of the Asian hy-
pertension population, a new randomized controlled trial 
of RDN to target morning hypertension in the region could 
be valuable. Japanese observational studies including the 
community-based Ohasama population42 and the general 
practitioner-based HOMED-BP (the Hypertension Objective 
Treatment Based on Measurement by Electrical Devices of 
Blood Pressure), J-HOP, and HONEST (The Home BP meas-
urement with Olmesartan Naive patients to Establish Standard 
Target blood pressure) studies of antihypertensive medica-
tion43–46,86 clearly demonstrated that morning hypertension 
is significantly associated with the risk of CVD, especially 
stroke, regardless of office BP. The morning BP surge contrib-
utes to morning hypertension and is strongly associated with 
risk of stroke independent of 24-hour BP.87 Morning BP surge 
and morning hypertension partly contribute to sympathetic hy-
peractivity in the morning.5,87 Morning hypertension is easily 
and accurately detected by home BP monitoring) and about 
half of medicated hypertensive patients are uncontrolled for 
morning hypertension in clinical trials (supplemental figure).7
The second target of RDN might be nocturnal uncontrolled 
hypertension. This could be especially important because the 
24-hour BP-lowering effect of antihypertensive drugs may be 
partially limited by morning dosing habits. Nocturnal hyper-
tension is closely associated with various diseases, including 
obstructive sleep apnea (OSA), chronic kidney disease, and dia-
betes mellitus.5,58 In particular, OSA is known as a cause of neu-
rogenic hypertension with sympathetic hyperactivity triggered 
by hypoxic sleep apnea episodes.50 The hypersympathetic drive 
induced by OSA episodes induces a BP surge during sleep.88 
In a post hoc analysis of patients enrolled in SYMPLICITY 
HTN-3 who had OSA, averaged nighttime BP was not reduced 
by RDN, but significant reductions were seen in maximum and 
peak nighttime BP values (Figure 6).89 In the direct study, which 
used recently developed hypoxia-trigger home BP monitoring 
in OSA patients, morning BP and peak nighttime BP trig-
gered by OSA episodes were significantly reduced after RDN 
and by bedtime dosing of sympatholytic agents (α-blocker/β-
blocker),90 indicating that the OSA-related sleep BP surge is 
triggered by sympathetic overdrive induced by obstructive 
apneas. The specific nighttime BP-lowering effect of RDN in 
OSA patients is an interesting area for research.
Figure 5. Possible indications for renal denervation. BP indicates blood pressure; and SBP, systolic blood pressure.85
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Future clinical studies of RDN should continue to focus 
on the reduction of 24-hour SBP assessed by ambulatory BP 
monitoring as the primary end point. Visit-to-visit office, am-
bulatory, and home BP variability are all associated with CVD 
events, independently of average BP. Potentially, modern 
big data statistical techniques could be applied to new larger 
out-of-office BP data sets, obtained using home BP monitor-
ing, ambulatory BP monitoring, and wearable BP monitor-
ing devices, to more accurately detect the effects of RDN on 
average BP and BP variability.91,92 Recently, an advanced in-
formation communication technology-based ambulatory BP 
monitoring system has been developed that integrates an acti-
graph, thermometer, and barometer, allowing monitoring of 
home BP and environmental conditions in a single system.91,93 
Using this system, the effect of RDN on sympathetic drive-
induced BP variability during daily life could be evaluated.
Potential New Indications
In addition to uncontrolled hypertension, the potential of RDN 
has been evaluated in other clinical situations. These include 
metabolic syndrome,94,95 OSA,96 atrial fibrillation,97,98 ventric-
ular arrhythmias,99,100 heart failure,101–103 and chronic kidney 
disease.104–106 Based on positive results in pivotal trials, it is 
expected that there will be indications for RDN beyond hy-
pertension. Evaluation of the effects of RDN on metabolic 
syndrome may be particularly important given the rapidly 
increasing prevalence of metabolic syndrome in East and 
South East Asian areas.107 Likewise, OSA is a promising target 
for cardiovascular risk reduction via RDN because of its as-
sociation with neurogenic hypertension. However, additional 
longer-term data are required.
Figure 6. Impact of renal denervation (RDN) on 
nighttime blood pressure changes in patients 
with history of resistant hypertension and 
obstructive sleep apnea in the SYMPLICITY 
HTN-3 trial. Changes in nighttime blood 
pressure reduction at 6 mo after RDN were 
predominant in the subgroup of patients with 
(A)  vs without (B) obstructive sleep apnea.89
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Summary: RDN Future Research
• Uncontrolled morning hypertension and residual noc-
turnal hypertension despite antihypertensive pharma-
cotherapy are promising targets for the use of RDN 
in Asia.
• Cardiovascular diseases, including congestive heart fail-
ure, chronic kidney disease, and atrial and ventricular 
arrhythmias, are all associated with hypertension and 
sympathetic hyperactivity and might, therefore, benefit 
from RDN-associated reductions in BP and circulating 
volume; a direct effect on sympatholytic activity on tar-
get organs is also possible.
• OSA is a promising target for cardiovascular risk reduc-
tion via RDN because of its association with neurogenic 
hypertension.
Conclusion and Perspectives
The present recommendations seem both prudent and timely con-
sidering the unmitigated cardiovascular risk currently facing the 
large population with uncontrolled hypertension in Asia. Because 
of the unique manifestations of hypertension-related CVD and 
higher rates of uncontrolled hypertension, Asian patients could 
particularly benefit from RDN therapy. Available evidence sug-
gests that RDN should not be considered a therapy of last re-
sort but as an initial therapy option that may be applied alone 
or as a complementary therapy to antihypertensive medication. 
Furthermore, the therapy should not necessarily be restricted to 
clinical trials or centers of excellence, as long as proper proce-
dural training and internal cooperation between referring physi-
cians, hypertension specialists, and operators has been achieved. 
Evidence also supports consideration of RDN for sympathetically 
driven hypertension, including resistant hypertension, and any 
patient preference for device therapy should be factor in shared 
clinical decisions. New randomized clinical trials of RDN in Asia 
focusing on uncontrolled morning hypertension and, ultimately, 
clinical outcomes are needed to further optimize treatment.
Summary of ARDeC Consensus Panel 
Recommendations
• RDN could serve as a BP-lowering strategy alone or in 
combination with pharmacotherapy for Asian patients in 
situations where BP targets are difficult to achieve and 
maintain.
• The decision to perform RDN should consider patient 
preference as part of a patient-physician shared deci-
sion-making process.
• RDN should be considered for hypertensive patients 
with higher cardiovascular risk including the following:
– Resistant or masked uncontrolled hypertension
–  Uncontrolled hypertension with established ath-
erosclerotic cardiovascular disease such as stroke, 
coronary artery disease, aortic dissection, as well as 
heart failure
–  Intolerant of, or nonadherent to, antihypertensive 
drug therapy
–  Combined uncontrolled hypertension or lower pulse 
pressure (<100 mm Hg)
–  Increased 24-hour ambulatory heart rate (>74 
beats/min)
• Therapy should not necessarily be restricted to clinical tri-
als or centers of excellence if proper procedural training 
and internal cooperation between referring physicians, 
hypertension specialists and proceduralists is achieved.
• Completeness of the RDN procedure should be ensured 
by increasing the number of ablations, ensuring circum-
ferential lesion distribution, treating the main artery 
plus side branches, and even accessory branches when 
possible.
• RDN should be considered in uncontrolled morning hy-
pertension and residual nocturnal hypertension treated 
with antihypertensive pharmacotherapy.
• A randomized controlled trial of RDN targeting morn-
ing hypertension in Asia is recommended to identify pa-
tients with increased procedural benefit.
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